New Guidance on Using High-Efficacy DMTs in Multiple Scleros

High-efficacy therapies for multiple sclerosis have improved disease outcomes for many patients, but physicians are uncertain when to use them.

Related Keywords

Sweden , Japan , Canada , Denmark , Toronto , Ontario , Barcelona , Comunidad Autonoma De Cataluna , Spain , Japanese , Roche Genentech , Merck Serono , Gavin Giovannoni , Patricia Coyle , Dalia Rotstein , Xavier Montalban , Glaxosmithkline , Genentech , European Academy Of Neurology , Hebron University Hospital , Jazz Pharmaceuticals , Merck Co , Sclerosis Centre Of Catalonia At Vall , Novartis , University Of Toronto , Sanofi Aventis , Queen Mary University Of London , Biogen Idec , Serono , Research In Multiple Sclerosis , European Committee For Treatment , European Committee , Multiple Sclerosis , Care Center , Stony Brook , European Academy , Expanded Disability Status Scale , Multiple Sclerosis Centre , Induction Therapy , Queen Mary University , Roche Canada , Atara Bio , Japanese Tobacco , Multiple Sclerosis Ms , Us , Disease Modifying Therapy , Mt , Neoadjuvant , Disability , Magnetic Resonance Imaging Mri , Magnetic Resonance Imaging , Ri , Maging Magnetic Resonance , Poverty , Inancial Hardship , Social Determinants Of Health , Social Issues , Autoimmune Disease , Biologic Therapy , Immunomodulator , Lenalidomide , Secondary Progressive Multiple Sclerosis , Pms , Aggression , Anxiet ,